Testosterone therapy is a common treatment for hypogonadism, but concerns have been raised that it increases a man's risk of developing prostate cancer. In three parallel prospective studies, 1,023 men received testosterone therapy, either from a urologist (two groups) or at an academic andrology centre. 11 patients in total were diagnosed with prostate cancer, with incidence per 10,000 patient years of 54.4 and 30.76 in the urology settings, and 0.00 in the andrology centre setting, suggesting that testosterone therapy is not associated with increased prostate cancer risk.
References
Haider, A. et al. Incidence of prostate cancer in hypogonadal men receiving testosterone therapy: observations from five year-median follow-up of three registries. J. Urol. 10.1016/j.juro.2014.06.071
Rights and permissions
About this article
Cite this article
Low risk of prostate cancer after testosterone therapy. Nat Rev Urol 11, 424 (2014). https://doi.org/10.1038/nrurol.2014.175
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.175
